Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q1 2018 call → NOWe need to determine if management explains where the company's business is going by narrating what its counterparties are themselves doing and scaling. The key is whether management's forward account is substantially about the growth, expansion, ramp, adoption, or program build-out of specific customers, partners, etc., that the company already supplies or serves, such that the company's own coming volume is presented as a consequence of those parties' own trajectories. Let's analyze the transcript. The call is about CVS Health's Q1 2018 earnings. Management discusses the Aetna acquisition, integration, and various business segments. They talk about PBM, Retail/Long-Term Care, etc. Key points: They discuss the 2019 selling season, retention rates, RFP opportunities. They mention that they are more than halfway through renewals. They talk about partnerships with PBMs and health plans, and how they are seeing uptick from Optum and Cigna clients. They mention that their initiatives are driving growth. They also discuss the Anthem implementation, which is a contract they will administer beginning in 2020. They talk about the investments they are making for Anthem. But the question is: does management narrate what counterparties are themselves doing and scaling? For example, do they talk about how their clients are expanding, ramping up, building out programs? They mention that they have partnerships with other PBMs and health plans, and that they see opportunities for 2020 and beyond. They mention that they have seen an uptick by a number of both Optum and Cigna clients of many CVS Pharmacy and MinuteClinic programs. That is about their own programs being adopted by those clients. But is that about the counterparties' own trajectories? It's more about the company's own initiatives driving adoption. They also talk about the Anthem implementation. They are preparing to administer that contract starting in 2020. That is a specific counterparty, but the narrative is about the company's preparation and costs, not about Anthem's own expansion. They don't describe Anthem's own growth or scaling. They talk about the PBM selling season, but that's about their own selling efforts. They talk about the Retail/Long-Term Care segment, and how they are benefiting from broader relationships with payers and preferred positions in Medicare Part D networks.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.